Research Summary
Analyzed using Evidence Intelligence™

AndroidAPS Improves Glycemic Control in Type 1 Diabetes

Last updated July 12, 2026

Key finding

Glycemic outcomes attained were similar to commercial AID systems.

AndroidAPS, an open-source automated delivery system, in adults with type 1 diabetes.

Quick read

Study at a glance

The essential study design details in one scan.

EvidenceScore™

Moderate

Study type

RCTs

Follow-up

Short-Term (≤3 mo)

Risk of bias

Some Concerns

Save research, organize studies, and quickly find important evidence again.

Plain-language summary

What this paper says

A plain-language read of the study’s main message and where it applies.

Study focus

AndroidAPS, an open-source automated delivery system, in adults with type 1 diabetes.

Clinical relevance

This study evaluated AndroidAPS, an open-source automated delivery system, in adults with type 1 diabetes.

Keep in mind

Limitations were not clearly described in the extracted text.

Published in

Journal Reference

Publication details and source links for this paper.

Tom MW, Martin DB. Assessing the Glycemic Efficacy and Safety of AndroidAPS in Adults with Type 1 Diabetes. Journal of Diabetes Science and Technology. 2023;18(4):897-898. doi:10.1177/19322968231208216

Evidence network

How this study fits

Understand where this research contributes within the broader evidence network.

Evidence Context

This study contributes evidence to AndroidAPS - Treatment A and Glycemic control comparison to commercial AID systems, Safety events.

Primary intervention

AndroidAPS - Treatment A

Primary outcomes

  • Glycemic control comparison to commercial AID systems
  • Safety events

Evidence relationships

Intervention and outcome relationships this study adds to the evidence network.

2
Evidence pairs
2
Relationships
0
Evidence topics
contributes_evidence

Editorial context

Why this study matters

See why this paper is useful beyond its individual results.

Evidence network role

This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.

Limited contributionModerate confidenceNetwork score: 42

0

Related topics

2

Evidence pairs

0

Related studies

Why it is useful

  • Contributes to 2 evidence relationships
  • Includes primary outcome data
  • Linked to 0 direct semantic evidence topics

Core evidence

Study findings

The primary outcomes reported in this study.

Glycemic control comparison to commercial AID systems

AndroidAPS - Treatment A → Glycemic control comparison to commercial AID systems

AndroidAPS - Treatment A → Glycemic control comparison to commercial AID systems

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
100
Very Positive
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

Safety events

AndroidAPS - Treatment A → Safety events

AndroidAPS - Treatment A → Safety events

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
50
Neutral
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

Connected Evidence

Explore related studies, evidence collections, and research questions.

Relationships organized using the Dediabetes Evidence Intelligence™ framework.

This study contributes to evidence on AndroidAPS - Treatment A and Glycemic control comparison to commercial AID systems, AndroidAPS - Treatment A and Safety events.

Related evidence relationships

Explore in Evidence Explorer

This study contributes to the evidence on the following intervention-outcome relationships.

Questions answered by this study

Generated from the study's connected evidence using Evidence Intelligence™.

Does AndroidAPS - Treatment A improve glycemic control comparison to commercial aid systems?

Emerging Evidence

AndroidAPS - Treatment A appears to improve Glycemic control comparison to commercial AID systems.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

  1. 1

    Glycemic control comparison to commercial AID systems

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

  • Only one supporting study is available.
  • Consistency cannot yet be determined.
  • Population details are unavailable.
1 supporting studyUpdated: Jul 2026

Does AndroidAPS - Treatment A affect safety events?

Emerging Evidence

Current evidence does not show a clear benefit of AndroidAPS - Treatment A for Safety events.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

  1. 1

    Safety events

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

  • Only one supporting study is available.
  • Consistency cannot yet be determined.
  • Population details are unavailable.
1 supporting studyUpdated: Jul 2026
Learn how Evidence Intelligence™ works

Next steps

Continue your research

Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.

No ads. No tracking.

Focused on evidence, not advertising.

Secure & private

Your data is always protected.

Always up to date

New studies added every day.